These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 19654286

  • 1. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance.
    Nomura M, Ishii H, Kawakami A, Yoshida M.
    Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1030-8. PubMed ID: 19654286
    [Abstract] [Full Text] [Related]

  • 2. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
    Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M, Ishii H, Yoshida M.
    FEBS Lett; 2007 Dec 11; 581(29):5664-70. PubMed ID: 18022391
    [Abstract] [Full Text] [Related]

  • 3. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.
    Sugizaki T, Watanabe M, Horai Y, Kaneko-Iwasaki N, Arita E, Miyazaki T, Morimoto K, Honda A, Irie J, Itoh H.
    Endocrinology; 2014 Aug 11; 155(8):2810-9. PubMed ID: 24773344
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Niemann-Pick C1-like 1 overexpression facilitates ezetimibe-sensitive cholesterol and beta-sitosterol uptake in CaCo-2 cells.
    Yamanashi Y, Takada T, Suzuki H.
    J Pharmacol Exp Ther; 2007 Feb 11; 320(2):559-64. PubMed ID: 17135346
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vivo responsiveness to ezetimibe correlates with niemann-pick C1 like-1 (NPC1L1) binding affinity: Comparison of multiple species NPC1L1 orthologs.
    Hawes BE, O'neill KA, Yao X, Crona JH, Davis HR, Graziano MP, Altmann SW.
    Mol Pharmacol; 2007 Jan 11; 71(1):19-29. PubMed ID: 17005902
    [Abstract] [Full Text] [Related]

  • 10. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
    Zheng S, Hoos L, Cook J, Tetzloff G, Davis H, van Heek M, Hwa JJ.
    Eur J Pharmacol; 2008 Apr 14; 584(1):118-24. PubMed ID: 18329014
    [Abstract] [Full Text] [Related]

  • 11. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
    Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JR, Girard J, Postic C.
    Diabetes; 2006 Aug 14; 55(8):2159-70. PubMed ID: 16873678
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1.
    Ge L, Wang J, Qi W, Miao HH, Cao J, Qu YX, Li BL, Song BL.
    Cell Metab; 2008 Jun 14; 7(6):508-19. PubMed ID: 18522832
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.